Drug-associated interstitial lung disease: A diagnostic challenge;Les pneumopathies infiltrantes diffuses d'origine médicamenteuse: Un problème avant tout diagnostique

Revue de Pneumologie Clinique

Volumn 61, Issue 3, 2005, Pages 179-185

  Mayaud, Charles ^a   Fartoukh, Muriel ^a   Parrot, Antoine ^a   Cadranel, Jacques ^a   Milleron, Bernard ^a   Akoun, Georges ^a  

^a HÔPITAL TENON   (France)

Author keywords

Bronchoalveolar lavage; Causality; Drugs; Interstitial lung disease

Indexed keywords

ACEBUTOLOL; AMIODARONE; AMPHOTERICIN B; AMPICILLIN; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CELIPROLOL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLECAINIDE ACETATE; MALOPRIM; METHOTREXATE; MINOCYCLINE; NILUTAMIDE; NITROFURANTOIN; NITROSOUREA; PENICILLAMINE; PENICILLIN G; PROPRANOLOL DERIVATIVE; SALAZOSULFAPYRIDINE; TETRACYCLINE; VINCRISTINE;

CYTOTOXICITY; DISEASE COURSE; EOSINOPHIL; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG HEMORRHAGE; LYMPHOCYTE; NEUTROPHIL; PATHOPHYSIOLOGY; REVIEW;

EID: 23144439636     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8417(05)84810-2     Document Type: Review

References (47)

1. Israel-Biet D, Cadranel J. Mécanismes physiopathologiques des pneumopathies médicamenteuses chez l'homme. Rev Mal Respir 1996;13:127-32.
2. Delaunois L. Mechanisms of pulmonary toxicology. Clin Chest Med 2004;25:1-14.
3. Nemery B, Bast A, Behr J, Borm P, Bourke S, Camus P, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J 2001;18(Suppl 32):30S-42S.
4. Evans WE, Mc Leod HL. Pharmacogenomics-drug deposition, drug targets and side effects. N Engl J Med 2003;348:538-49.
5. Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicol Lett 2000;112-113:171-6.
6. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 2000;112:421-32.
7. Repetto MR, Repetto M. Therapeutic, toxic and lethal concentration of 73 drugs affecting respiratory system in human fluids. J Toxicol Clin Toxicol 1998;36:287-93.
8. Lazo JS, Hoyt DG, Sebti SM, Pitt BR. Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol Ther 1990;47:347-58.
9. Smith RE, Strieter RM, Phan SH, Hunkel SL. CC chemokines: novel mediators in the profibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol 1996;15:693-702.
10. Hagimoto N, Kuwano K, Nomoto Y. Apoptosis and expression of the FAS/FAS ligand mRna in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997;16:91-101.
11. Keane MP, Belperio JA, Arenberg DA. INF-gamma-induced pulmonary fibrosis via inhibiton of angiogenesis. J Immunol 1999;163:5686-92.
12. Ghosh S, Mendoza T, Ortiz L, Hoyle G, Fermin C, Brody A, et al. Bleomycin sensitivity in mice expressing dominant-negative p53 in the lung epithelium. Am J Respir Crit Care Med 2002;166:890-7.
13. Flieder DB, Travis WD. Pathologic characteristis of drug-induced lung disease. Clin Chest Med 2004;25:37-45.
14. Camus P, Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity. Clin Chest Med 2004;25:65-75.
15. Camus P, Rosenow EC III. Iatrogenic lung disease. Clin Chest Med 2004;25:XIII-XIX.
16. Travis W, King T, Bateman E, Lynch D. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
17. Van Mieghem W, Coolen L, Malysse I, Lacquet L, Deneffe G, Demedts M. Amiodarone and the development of ARDS after lung surgery. Chest 1994;105:1642-5.
18. Alarcon G, Kremer J, Macaluso M, Weinblatt M, Cannong G, Palmer W, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. Ann Intern Med 1997;127:356-64.
19. Cooper J, White D, Matthay R. Drug-induced pulmonary disease. Part 1-Cytotoxic drugs. Am Rev Respir Dis 1986;133:321-40.
20. Cooper J, White D, Matthay R. Drug-induced pulmonary disease. Part 2-Noncytotoxic drugs. Am Rev Respir Dis 1986;133:488-505.
21. Rosenow EC III, Myers J, Swensen S, Pisani R. Drug-induced pulmonary disease. An update. Chest 1992;102:239-50.
22. Foucher P, Biour M, Blayac J, Godard P, Sgro C, Kuhn M, et al. Drugs which may injure the respiratory system. Eur Respir J 1997;10:265-79.
23. Malik S, Myers J, DeRemee R, Specks U. Lung toxicity with cyclophosphamide use: two distict patterns. Am J Respir Crit Care Med 1996;154:1851-6.
24. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the litterature. Am J Clin Oncol 2002;25:96-100.
25. Rosado M, Donna E, Ahn Y. Challenging problems in advanced malignancy: imatinib mesylate (Gleevec)-induced interstitial pneumonitis. J Clin Oncol 2003;21:3171-3.
26. Etienne B, Perol M, Nesme P, Vuillermoz S, Robinet G, Guerin J. Pneumopathie interstitielle diffuse aiguë sous docétaxel (Taxotère). Rev Mal Respir 1998;15:199-203.
27. Cohen M, Williams G, Sridhara R. FDA drug-approval summary: gefitinib (Iressa) tablets. Oncologist 2003;8:303-6.
28. Mayaud C, Mangiapan G, De Groote E, Parrot A, Cadranel J, Milleron B. Pneumopathies médicamenteuses s'accompagnant d'insuffisance respiratoire aiguë. Rev Mal Respir 1996;13:321-5.
29. Nicolls M, Terada L, Tuder R, Prindiville S, Schwarz M. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998;158:1302-5.
30. Dhillon SS, Singh D, Doe N, Qadri A, Ricciardi S, Schwarz M. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999;116:1485-8.
31. Kalra S, Bell M, Rihal C. Alveolar hemorrhage as a complication of treatment with abciximab. Chest 2001;120:126-31.
32. Jung J, Choi J, Hahn S, Min C, Kim C, Park S. Radiologic features of all-trans-retinoic acid syndrome. AJR Am J Roentgenol 2002;178:475-80.
33. Kharabsheh S, Abendroth C, Kozak M. Fatal pulmonary toxicity occuring within two weeks of initiation of amiodarone. Am J Cardiol 2002;89:896-8.
34. Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004;25:25-35.
35. Israel-Biet D, Danel C, Costabel U. The clinical role of BAL in drug-induced pneumonitis. Eur Respir Rev 1992;2:97-9.
36. Akoun G, Cadranel J, Blanchette G, Milleron B, Mayaud C. Bronchoalveolar lavage cell data in amiodarone-associated pneumonitis. Chest 1991;99:1177-82.
37. Akoun G, Cadranel J, Milleron B, Flammang d'Ortho M, Mayaud C. Bronchoalveolar lavage cell data in 19 patients with drug-associated pneumonitis (except amiodarone). Chest 1991;99:98-104.
38. Pfitzenmeyer P, Foucher P, Piard F, Coudert B, Braud M, Gabez P, et al. Nilutamide pneumonitis: a report of eight patients. Thorax 1992;47:622-7.
39. Sitbon O, Bidel N, Dussopt C. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med 1994;154:1633-40.
40. Tomioka R, King T. Gold-induced pulmonary disease: clinical features, outcome and differenciation from rheumatoid lung disease. Am J Respir Crit Care Med 1997;155:1011-20.
41. Fuhrman C, Parrot A, Wislez M, Prigent H, Boussaud V, Bernaudin J, et al. Spectrum of CD4 to CD8 T-cells ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001;164:1186-91.
42. Begaud B, Evreux J, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 1985;40:111-8.
43. Fournier M, Camus P, Bonichou C, Danan G, Begaud B, Castot A, et al. Pneumopathies interstitielles: critères d'imputation à un médicament. Presse Med 1989;18:1333-6.
44. Amery W. Causality assessment of individuals adverse drug events. Int J Risk Safety Med 1994;5:125-44.
45. Mas A, Jordana R, Valles J, Cerventes M. Recurrent hydrochlorothiazide- induced pulmonary edema. Intens Care Med 1998;24:363-5.
46. Gallerani M, Manzoli N, Fellin R, Simonato M, Orzincolo C. Anaphylactic shock and acute pulmonary edema after a single oral dose of acetazolamide. Am J Emerg Med 2002;20:371-2.
47. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986;58:1428-36.